Orthofix Medical Inc at JMP Securities Life Sciences Virtual Conference Transcript
Great, thanks, everybody. And next up on our medtech slate, we have Orthofix. We have CEO, Jon Serbousek; and CFO, Doug Rice, and we're going to jump right in. So thank you, gentlemen, for attending virtually this year. And you know, it's a tough question to start off with everyone, but looking at last year -- certainly an interesting one. But, Jon, I'd love to get your thoughts at a high level coming off of COVID -- coming out of COVID, sort of how Orthofix handled the pandemic and what you think the setup is heading into hopefully a more normalized year in 2021.
Yes, Dave. Thanks, thank you very much, and first of all, thank you for the invitation; it's a pleasure to be with you today. 2020 was definitely an interesting year. I would say it's the most interesting year I have had from a business process execution in my entire career. We learned a lot in that, but I would say that we had just begun to transform our business in February 2020 and [COVID hit].
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |